Selinexor- Karyopharm Therapeutics

Alternative Names: ATG-010; CRM1-nuclear-export-inhibitor; KPT-330; NEXPOVIO; ONO 7705; Selinisso; TP-53; XPOVIO

Latest Information Update: 04 Jul 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Karyopharm Therapeutics
Developer Antengene Corporation; Cardiff University; Grupo Espanol de Investigacion en Sarcomas; Karyopharm Therapeutics; Menarini; Ono Pharmaceutical; Promedico; University of Texas Southwestern Medical Center
Class Acrylamides; Anti-infectives; Antineoplastics; Antivirals; Fluorinated hydrocarbons; Foot disorder therapies; Hydrazines; Pyrazines; Skin disorder therapies; Small molecules; Triazoles
Mechanism of Action Exportin 1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Myelofibrosis; Soft tissue sarcoma
New Molecular Entity Yes

Highest Development Phases

Marketed Diffuse large B cell lymphoma; Multiple myeloma
Phase III Endometrial cancer; Liposarcoma; Myelofibrosis
Phase II/III Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Phase II Colorectal cancer; COVID 2019 infections; Malignant melanoma; Ovarian cancer; Peripheral T-cell lymphoma; Thrombocytopenia; Thymic epithelial tumour; Thymoma; Triple negative breast cancer
Phase I/II Gastrointestinal stromal tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
Phase I Liver cancer
No development reported B-cell lymphoma; Cervical cancer; Chronic lymphocytic leukaemia; Extranodal NK-T-cell lymphoma; Glioma; HER2 positive breast cancer; Neuroendocrine tumours; Osteosarcoma; Sepsis; Soft tissue sarcoma
Discontinued Cutaneous T-cell lymphoma; Diabetic foot ulcer; Gastric cancer; Glioblastoma; Oesophageal cancer; Prostate cancer; Rectal cancer; Richter's syndrome; Small cell lung cancer; Squamous cell cancer

Most Recent Events

26 Jun 2024 Antengene expects NDA approval in Thailand, Malaysia and Indonesia in the H2 of 2024
31 May 2024 Efficacy and adverse events data from a phase I/II trial in Non-small Cell Lung Cancer presented at the 60^th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
31 May 2024 Efficacy and adverse events data from a phase I/II TOUCH trial in NK/T-cell lymphoma presented at the 60^th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight